MAPT and Alzheimer disease: This finding was supported by another study where p-tau 181 was elevated in the CSF of patients with amyloid pathology and Braak NFT ≥ III detected by Aβ and Tau PET screening in early AD stages, confirming an escalating trend with disease progression [42,43].